Abstract
Objective: To investigate the impact of vericiguat on ventricular remodeling and cardiac function in patients with chronic severe heart failure. Methods: From January 2021 to June 2023, 93 patients with chronic severe heart failure admitted to our hospital were randomly assigned to two groups using an envelope. The observation group (46 patients) and the control group (47 patients). The control group received quadruple therapy, while the observation group received additional vericiguat treatment based on the control group's regimen. The levels of ventricular remodeling (left ventricular posterior wall thickness, LVPWT; left ventricular mass index, LVMI) and cardiac function (left ventricular end-diastolic volume index, LVEDVI; left ventricular ejection fraction, LVEF) were compared between the two groups. Results: After treatment, both LVPWT and LVMI decreased significantly in both groups, with a greater decrease observed in the observation group compared to the control group (P < 0.05). Additionally, LVEDVI and LVEF increased significantly, with the observation group showing better improvement than the control group (P < 0.05). Conclusion: The addition of vericiguat to quadruple therapy for patients with chronic severe heart failure can improve ventricular remodeling and cardiac function levels, making it worthy of promotion.
References
[1] Bao Y, Wang M, Ma J. Study on the efficacy of vericiguat in patients with heart failure with reduced ejection fraction. Mod Med Health. 2024;40(16):2764-7.
[2] Yang W, Guo Q, Guo T. New progress in the treatment of heart failure with reduced ejection fraction with vericiguat. Yunnan Med J. 2022;43(6):98-101.
[3] Wang Q, Niu J, Zhou Y, et al. Effect of sacubitril/valsartan combined with vericiguat in the treatment of chronic heart failure and its impact on cardiac function, cardiac structural remodeling, and vascular endothelial function. Hainan Med J. 2024;35(14):1991-6.
[4] Wilcox CS, Testani JM, Pitt B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. Hypertension. 2020;76(4):1045-54.
[5] Chen D, Wang C. Clinical efficacy of vericiguat combined with quadruple therapy for heart failure. Clin Rational Drug Use. 2024;(15).
[6] Borlaug B. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17(9):559-573.
[7] Work report of China Heart Failure Centre. (2021) - current situation of diagnosis and treatment of patients with heart failure. Chin J Interv Cardiol. 2022;30(5):328-36.
[8] Krittanawong C, Britt WM, Rizwan A, et al. Clinical Update in Heart Failure with Preserved Ejection Fraction. Curr Heart Fail Rep. 2024;21(5):461-484. doi:10.1007/s11897-024-00679-5
[9] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed). 2022;75(6):523.
[10] Zhang Y, Wang L, Liu X. Impact of vericiguat on cardiac function, exercise tolerance, and quality of life in patients with heart failure with reduced ejection fraction. Clin Med Eng. 2024;31(11):1379-80.
[11] Liu J, Zhang Y, Wang L, et al. Analysis of the therapeutic effect of vericiguat combined with "new quadruple" drug on patients with dilated cardiomyopathy and heart failure. J Nanjing Med Univ (Nat Sci Ed). 2024;44(12):1682-9.
[12] Kennedy S, Gaggin H. Leveraging Biomarkers for Precision Medicine in Heart Failure. J Card Fail. 2023;29(4):459-462.
[13] Zeng L, Li X. Observation of the effect of vericiguat on the treatment of chronic heart failure. Chin Prescr Drugs. 2025;23(2):69-71.
[14] Zhang J, Zhang Y, Zhou L. National heart failure guide 2023 (simplified version). Chin Circ J. 2023;38(12):1207-38.
How to cite this paper
Impact of Vericiguat on Ventricular Remodeling and Cardiac Function in Patients with Chronic Severe Heart Failure
How to cite this paper: Xiaowei Wang, Nan Zhang. (2025) Impact of Vericiguat on Ventricular Remodeling and Cardiac Function in Patients with Chronic Severe Heart Failure. International Journal of Clinical and Experimental Medicine Research, 9(2), 236-239.
DOI: http://dx.doi.org/10.26855/ijcemr.2025.03.013